Patients with Cystic Fibrosis have increased oxidative stress and impaired antioxidant systems. Under certain conditions, docosahexaenoic acid (DHA) intake may have a favorable role in reducing redox status.

In this randomized, double-blind, cross-over study, DHA (Pro-Mind) and placebo (sunflower oil) capsules, will be given, daily to 10 patients, 5 mg/kg for 2 weeks then 10 mg/kg for the next 2 weeks. Biomarkers of lipid peroxidation and vitamin E levels will be measured. Plasma and platelet lipid compositions will be determined.

Inclusion Criteria:

• Male with confirmed diagnosis of Cystic Fibrosis with a sweat chloride > 60 mmol/L and a pancreatic insufficiency.
• Subjects will be aged between 6 and 18 years and be prepubescent, or aged between 18 and 30 years
• Body weight > 26 kg
• Stable CF disease as judged by the investigator.
• Subjects must have an Forced Expiratory Volume at one second > 40 % of predicted normal for age, sex and height at the screening visit.
• Subjects should not have enteral or parenteral nutrition.
• No periodic IV lipidic emulsion administration. Subjects must not consume food supplements rich in OMEGA-3 on a regular basis.

Exclusion Criteria:

• Subjects with cirrhosis and portal hypertension.
• Subjects with Cystic fibrosis related diabetes.
• Concomitant participation in another clinical study.
• Known allergy or intolerance to the active principle.
• Subjects with major blood coagulation anomalies, patients under anticoagulants or aspirin (long term therapy).
• Subjects on a transplant waiting list.